Genzyme (NASDAQ: GENZ) reported a Phase II trial of its leukemia drug Campath (monoclonal antibody targeting CD52) showed superiority at treating multiple sclerosis over Merck’s (NYSE: MRK) Rebif (Interferon beta-1a).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment